whitepaper

Article: Finding a (biomarker) needle in the haystack

Posted: 30 April 2021 | | No comments yet

Summary of a neurology publication by Alnylam Pharmaceuticals: large-scale protein screening identifies novel biomarker for onset and progression of lethal ATTRv amyloidosis.

In a study published in neurology, a group from Alnylam Pharmaceuticals used large-scale protein screening assays to simultaneously analyse many proteins in vast numbers of patient serum samples. This cutting-edge approach allowed them to discover a novel biomarker of hereditary transthyretin-mediated (ATTRv) amyloidosis disease onset and progression. ATTRv amyloidosis, caused by mutation of the transthyretin protein is a rare, adult-onset disease characterised by the accumulation of amyloid fibrils throughout the body, leading to progressive debilitation and death.












    To read this article in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of Olink

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Send this to a friend